Alexander Burchardt
About
Alexander Burchardt is a scholar working on Pathology and Forensic Medicine, Genetics and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Alexander Burchardt has authored 17 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pathology and Forensic Medicine, 4 papers in Genetics and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alexander Burchardt's work include Lymphoma Diagnosis and Treatment (10 papers), Acute Myeloid Leukemia Research (3 papers) and Neutropenia and Cancer Infections (3 papers). Alexander Burchardt is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Acute Myeloid Leukemia Research (3 papers) and Neutropenia and Cancer Infections (3 papers). Alexander Burchardt collaborates with scholars based in Germany, Austria and United States. Alexander Burchardt's co-authors include Oliver A. Cornely, Ray Hachem, Dimitrios P. Kontoyiannis, David Wexler, Ronan Courtney, Gopal Krishna, Gavin Corcoran, Andrew J. Ullmann, M. Martinho and Issam Raad and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Antimicrobial Agents and Chemotherapy.
In The Last Decade
Alexander Burchardt
17 papers receiving 486 citations
Peers
Alexander Burchardt
M. Michallet France
Ronan Le Calloch France
Effie Liakopoulou United Kingdom
Anne‐Claire Mamez Switzerland
Georgios Pongas United States
Sushrut Patil Australia
Sadaya Matano Japan
Liang‐Piu Koh Singapore
Chiara Ghiggi Italy
M. Essink Germany
Citations per year, relative to Alexander Burchardt Alexander Burchardt (= 1×)
peers
M. Michallet
Countries citing papers authored by Alexander Burchardt
Since
Specialization
Citations
This map shows the geographic impact of Alexander Burchardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Burchardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Burchardt more than expected).
Fields of papers citing papers by Alexander Burchardt
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alexander Burchardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Burchardt. The network helps show where Alexander Burchardt may publish in the future.
Co-authorship network of co-authors of Alexander Burchardt
This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Burchardt. A scholar is included among the top collaborators of Alexander Burchardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Burchardt. Alexander Burchardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jenks, Jeffrey D., Danila Seidel, Oliver A. Cornely, et al.. (2020). Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry. Mycoses. 63(5). 437–442.
2.
Sohlbach, Kristina, Stephan Metzelder, Ellen Wollmer, et al.. (2019). Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation. Leukemia & lymphoma. 60(8). 2056–2061.
3.
Rummel, Mathias, Christian Lerchenmüller, Manfred Hensel, et al.. (2019). Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). Blood. 134(Supplement_1). 343–343.
4.
Kobbe, Guido, Sabrina Pechtel, Fabian Zohren, et al.. (2018). Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance. Blood. 132(Supplement 1). 4149–4149.
5.
Rummel, Mathias, Christian Buske, Bernd Hertenstein, et al.. (2018). Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study). Clinical Lymphoma Myeloma & Leukemia. 18. S101–S103.
6.
Rummel, Mathias, Michael Koenigsmann, Kai Uwe Chow, et al.. (2018). Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).. Journal of Clinical Oncology. 36(15_suppl). 7515–7515.
7.
Rummel, Mathias, Georg Maschmeyer, Arnold Ganser, et al.. (2017). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.. Journal of Clinical Oncology. 35(15_suppl). 7501–7501.
8.
Gamerdinger, Ulrike, Alexander Brobeil, Mehmet Kemal Tur, et al.. (2014). Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. Pathology - Research and Practice. 210(6). 369–376.
9.
Dornes, Christian, et al.. (2014). Factor XIII Deficiency in Patients with Acute Leukemia: One out of Three Is Presenting with Deficiency. Blood. 124(21). 1528–1528.
10.
Rummel, Mathias, Christina Balser, Ulrich Kaiser, et al.. (2014). Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 124(21). 145–145.
11.
Rummel, Mathias, Georg Maschmeyer, Arnold Ganser, et al.. (2014). Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study. Blood. 124(21). 4407–4407.
12.
Rummel, Mathias, N. Niederle, Georg Maschmeyer, et al.. (2012). Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.. Blood. 120(21). 2724–2724.
13.
Rummel, Mathias, Christian Lerchenmüller, Richard Greil, et al.. (2012). Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenstrom's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).. Blood. 120(21). 2739–2739.
14.
Gaidzik, Verena I., Richard F. Schlenk, Peter Paschka, et al.. (2011). DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG. Blood. 118(21). 415–415.
15.
Ullmann, Andrew J., Oliver A. Cornely, Alexander Burchardt, et al.. (2006). Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection. Antimicrobial Agents and Chemotherapy. 50(2). 658–666.
16.
Basara, Nadežda, H. Baurmann, Karin Kolbe, et al.. (2005). Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplantation. 35(10). 1011–1018.
17.
Burchardt, Alexander, et al.. (1960). [Efficacy of hypertensin 2 in a case of severe cardiogenic shock resistant to therapy with noradrenalin].. PubMed. 58. 959–64.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by M. Michallet Breakdown of academic impact, for papers by Ronan Le Calloch Breakdown of academic impact, for papers by Effie Liakopoulou Breakdown of academic impact, for papers by Anne‐Claire Mamez Breakdown of academic impact, for papers by Georgios Pongas Breakdown of academic impact, for papers by Sushrut Patil Breakdown of academic impact, for papers by Sadaya Matano Breakdown of academic impact, for papers by Liang‐Piu Koh Breakdown of academic impact, for papers by Chiara Ghiggi Breakdown of academic impact, for papers by M. Essink